Nimotuzumab: Evidence of clinical benefit without rash

被引：57

作者：

Allan, DGP ^{[1
]}

机构：

[1] YM BioSci Inc, Mississauga, ON L4W 4Y4, Canada

来源：

ONCOLOGIST | 2005年 / 10卷 / 09期

关键词：

D O I：

10.1634/theoncologist.10-9-760

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

收藏

页码：760 / 761

页数：2

相关论文

共 5 条

[1] Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients [J].

Crombet, T ;

Osorio, M ;

Cruz, T ;

Roca, C ;

del Castillo, R ;

Mon, R ;

Iznaga-Escobar, N ;

Figueredo, R ;

Koropatnick, J ;

Renginfo, E ;

Fernández, E ;

Alvárez, D ;

Torres, O ;

Ramos, M ;

Leonard, I ;

Pérez, R ;

Lage, A .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) :1646-1654

[2]

CROMBET T, 2005, ANN M AM SOC CLIN ON

[3]

*IMCL SYST INC, 2004, ERB PACK INS CET PRE

[4] HER1/EGFR inhibitor-associated rash:: Future directions for management and investigation outcomes from the HER1/EGFR inhibitor rash management forum [J].

Pérez-Soler, R ;

Delord, JP ;

Halpern, A ;

Kelly, K ;

Krueger, J ;

Suresa, BM ;

von Pawel, J ;

Temel, J ;

Siena, S ;

Soulières, D ;

Saltz, L ;

Leyden, J .

ONCOLOGIST, 2005, 10 (05) :345-356

[5]

2005, YM BIOSCIENCES REPOR